EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study

Xijuan Lin iD, Ziwei Liu, Chen Yang, Junling Zhuang iD, Na Wei, Tingting Cui, Wenqi Zheng, Fang Ye, Xiaoqing Ding, Miao Chen, Bing Han

Cancer · 2026

DOI: 10.1002/cncr.70459 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Xijuan Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Hydrazines, Myelodysplastic Syndromes. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Science Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic strategies for myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs) remain suboptimal. Selinexor, an oral selective inhibitor of exportin 1, represents a mechanism‐based therapeutic approach. Preclinical and clinical evidence indicated synergistic antileukemic effects when selinexor was combined with hypomethylating agents or janus kinase inhibitors.

Methods

A prospective, single‐arm trial was conducted to evaluate selinexor plus either azacitidine (for MDS‐dominant features) or ruxolitinib (for MPN‐dominant features) in patients with MDS/MPN. The primary end point was the overall response rate at 6 months, which was assessed according to 2015 International Working Group criteria. Secondary end points included safety, progression, and survival.

Results

Twenty patients were enrolled (four with MDS‐dominant features, 16 with MPN‐dominant features). The median age was 66 years in the MDS group and 62.5 years in the MPN group. The overall response rate was 60% (12 of 20 patients; 95% confidence interval [CI], 36.1%–80.5%) overall, 75% (three of four patients; 95% CI, 31.1%–95.4%) in the MDS group, and 56.3% (nine of 16 patients; 95% CI, 33.2%–76.9%) in the MPN group. In the MDS group, clinical benefits included improvements in the total symptom score, erythroid response, platelet response, and spleen response (one in each of four patients; 25% for each response). In the MPN group, partial responses occurred in two of 16 patients (12.5%), and partial bone marrow responses occurred in three of 16 (18.8%), with additional benefits including spleen response (five of 16; 31.3%), total symptom score improvement (two of 16; 12.5%), erythroid response (two of 16; 12.5%), and platelet response (one of 16; 6.3%). Adverse events occurred in 14 patients (70%). Three patients experienced grade 3 or greater events, including two disease‐related fatalities. After a median follow‐up of 6 months (range, 2–15 months), one patient's disease transformed to acute myeloid leukemia.

Conclusions

Selinexor combined with azacitidine or ruxolitinib showed encouraging efficacy with a manageable safety profile in patients with MDS/MPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineHydrazinesMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesMyeloproliferative DisordersPyrazolesAgedAged, 80 and overFemaleHumansMaleMiddle AgedNitrilesProspective StudiesPyrimidinesTriazoles

Stichwörter der Autor:innen

azacitidineefficacymyelodysplastic syndrome/myeloproliferative neoplasmsruxolitinibselinexor

Substanzen

AzacitidineHydrazinesNitrilesPyrazolesPyrimidinesruxolitinibselinexorTriazoles

Autor:innen und Institutionen

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.
  • Department of Hematology, Beijing No. 6 Hospital, Beijing, China.
  • Department of Hematology, Chuiyangliu Hospital Affiliated with Tsinghua University, Beijing, China.
  • Department of Hematology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, China.

ORCID-Profile: Xijuan Lin, Junling Zhuang

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Medical Science Innovation Fund for Medical Sciences
  • National High Level Hospital Clinical Research Funding
  • Beijing Natural Science Foundation

Zitieren

APA

Lin, X., Liu, Z., Yang, C., Zhuang, J., Wei, N., Cui, T., Zheng, W., Ye, F., Ding, X., Chen, M., & Han, B. (2026). Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study. Cancer. https://doi.org/10.1002/cncr.70459

Vancouver

Lin X, Liu Z, Yang C, Zhuang J, Wei N, Cui T, et al. Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study. Cancer. 2026. doi:10.1002/cncr.70459

BibTeX
@article{Lin2026,
  author = {Lin, Xijuan and Liu, Ziwei and Yang, Chen and Zhuang, Junling and Wei, Na and Cui, Tingting and Zheng, Wenqi and Ye, Fang and Ding, Xiaoqing and Chen, Miao and Han, Bing},
  title = {Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70459}
}
Kostenlos starten →